Minerva Neurosciences, Inc. (NERV)
NASDAQ: NERV · Real-Time Price · USD
6.04
-0.51 (-7.79%)
At close: Mar 24, 2026, 4:00 PM EDT
6.10
+0.06 (0.99%)
After-hours: Mar 24, 2026, 7:55 PM EDT
Minerva Neurosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
8
Market Cap
261.38M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Orchestra BioMed Holdings | 33.48M |
| Foghorn Therapeutics | 30.91M |
| Armata Pharmaceuticals | 5.05M |
| AC Immune | 4.51M |
| Surrozen | 3.60M |
| ProKidney | 893.00K |
| Silence Therapeutics | 559.00K |
NERV News
- 12 days ago - Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum - GlobeNewsWire
- 13 days ago - Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates - GlobeNewsWire
- 20 days ago - Minerva Neurosciences to Participate in The Citizens Life Sciences Conference - GlobeNewsWire
- 7 weeks ago - Minerva Neurosciences, Inc. (NERV) Discusses Roluperidone as a Potential First Treatment for Negative Symptoms of Schizophrenia Transcript - Seeking Alpha
- 2 months ago - Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026 - GlobeNewsWire
- 4 months ago - Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors - GlobeNewsWire
- 4 months ago - Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates - GlobeNewsWire
- 5 months ago - Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved - GlobeNewsWire